Anti-trust regulator CCI clears Abu Dhabi Investment Authority minority stake acquisition in Intas Pharma
New Delhi: Anti-trust regulator Competition Commission of India (CCI) has cleared Platinum Owl's acquisition of a minority stake in Intas Pharmaceuticals. The proposed transaction involves a secondary acquisition by Platinum Owl of 3 percent of the equity shareholding of Intas (on an outstanding shares basis).
Intas is a public company engaged in the business of development, manufacture and marketing of pharmaceutical formulations and is the ultimate parent company of the Intas group. The products of Intas have a pan-India presence and have an extensive portfolio of specialty and generic pharmaceuticals exported globally from its manufacturing facilities in India.
Read also: Intas Pharma bags CDSCO panel nod to study Human Normal Immunoglobulin
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.